Mexico Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Mexico recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Mexico recombinant protein therapeutics cdmo market highlights
- The Mexico recombinant protein therapeutics cdmo market generated a revenue of USD 154.2 million in 2023 and is expected to reach USD 365.5 million by 2030.
- The Mexico market is expected to grow at a CAGR of 13.1% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 154.2 million |
| Market revenue in 2030 | USD 365.5 million |
| Growth rate | 13.1% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Mexico accounted for 0.7% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 811.0 million by 2030.
Interferons was the largest segment with a revenue share of 21.47% in 2023. Horizon Databook has segmented the Mexico recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is considered a significant offshoring and outsourcing country in Latin America, along with Brazil and Argentina, due to the partnership of the Central American Free Trade Agreement (CAFTA-DR) with the U.S. In addition, local & foreign investors are investing in the market due to recent economic growth and healthy government policies.
The biopharmaceutical companies are focusing on the Mexico market to obtain key services at cost-effective prices (lower-cost operations). Moreover, Mexico has strong Intellectual Property (IP) systems, attracting foreign companies to invest due to reduced obstacles in enforcing IP rights and their proper management & protection. Furthermore, Mexico is a hub for recombinant protein therapeutics CDMO services due to the significant savings in drug development costs.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Mexico Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
